Home・Lista de Ações・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Fechado

12.46 -5.39

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

12.89

Máximo

13.25

Indicadores-chave
By Trading Economics
Rendimento	-4.3M -18M
EPS	-0.19
Funcionários	37
EBITDA	-5.3M -17M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+128.51% upside

Dividendos
By Acuity
Próximos Ganhos	3 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	86M 1.2B
Abertura anterior	17.85
Fecho anterior	12.46

Corvus Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

14 de set. de 2026, 23:56 UTC

Blackstone Inc's shares are higher in after-market hours, reflecting positive movement despite broader U.S. equity weakness. No specific news was identified to explain the rise.

14 de set. de 2026, 23:56 UTC

RMR Group Inc shares are trading lower in after-market hours amid a broader U.S. equity decline influenced by rising crude oil prices and supply concerns.

14 de set. de 2026, 23:56 UTC

eHealth Inc. shares are trading higher in after-market hours, recovering from earlier lows despite broader market challenges, including a lower Nasdaq close.

14 de set. de 2026, 23:56 UTC

Geo Group Inc shares rose in after-market trading, despite broader market declines influenced by rising crude oil prices. No specific news was identified.

14 de set. de 2026, 23:56 UTC

Extra Space Storage shares are lower in after-market hours, reflecting broader market declines amid rising crude oil prices and ongoing stock performance weakness.

14 de set. de 2026, 23:56 UTC

CMS Energy shares are higher in after-market trading, reflecting a modest recovery from earlier fluctuations since Monday's close.

14 de set. de 2026, 23:56 UTC

Shares of Kinder Morgan advanced slightly during after-market hours. This occurred amid a broader market recovery attempt despite lower U.S. equities.

14 de set. de 2026, 23:56 UTC

Gentex Corp shares are higher in after-market trading, though no specific news was identified. The stock remains below its 20-day moving average.

14 de set. de 2026, 23:56 UTC

Shares of APA Corp are higher in after-market trading, remaining stable near the upper end of their one-month range amid broader market declines.

14 de set. de 2026, 23:56 UTC

Rogers Corp shares are higher in after-market trading, though no specific news explains the increase. Broader U.S. equities closed lower amid rising crude oil prices.

14 de set. de 2026, 23:56 UTC

First Hawaiian Inc shares are higher in after-market trading, despite broader market volatility and major indices closing lower. No specific news was identified for the move.

14 de set. de 2026, 23:52 UTC

Rush Enterprises shares traded lower after market hours, amid broader market concerns over rising crude oil prices and inflation ahead of the Federal Reserve meeting.

14 de set. de 2026, 23:52 UTC

Omnicom Group Inc shares are trading lower in after-market hours amid significant weakness in the Advertising sub-sector, remaining below the 20-day moving average.

14 de set. de 2026, 23:51 UTC

Liberty Energy Inc shares are higher in after-market trading, influenced by rising crude oil prices amid supply concerns from Saudi Arabia's pipeline shutdown.

14 de set. de 2026, 23:51 UTC

BILL Holdings Inc shares are lower in after-market hours following a pullback from earlier gains. No specific news was identified to explain the decline.

14 de set. de 2026, 23:51 UTC

News

Rimini Street shares lower in after-market trading despite announcing a partnership with Datacom to support Oracle and SAP software in Australia and New Zealand.

14 de set. de 2026, 23:51 UTC

National Healthcare Corp shares are higher in after-market trading, following a series of daily gains since Monday's close. No specific news was identified.

14 de set. de 2026, 23:51 UTC

Correlated Moves

Social Media

SLB NV shares are higher in after-market trading, reflecting strength amid rising crude oil prices and broader energy sector gains, despite mixed sentiment on social media.

14 de set. de 2026, 23:51 UTC

Devon Energy shares are higher in after-market hours, tracking a broader oil sector trend amid rising crude prices due to supply concerns from Saudi Arabia.

14 de set. de 2026, 23:51 UTC

China's Industrial Production YoY data set for release on September 15, 2026, with a forecasted growth of 4.8%, amid mixed market sentiment influenced by inflation and geopolitical tensions.

14 de set. de 2026, 23:51 UTC

China's Retail Sales YoY data for August 2026 expected to rise modestly by 0.8%, amid ongoing concerns over consumer spending and weak performance in key sectors.

14 de set. de 2026, 23:51 UTC

China's Fixed Asset Investment data release on September 15, 2026, forecasts a continued decline at -0.072%, raising concerns over economic stability amid ongoing property sector struggles.

14 de set. de 2026, 23:51 UTC

US Initial Jobless Claims Expected at 205,000 Amid Stable Labor Market Sentiment Ahead of September 17 Release.

14 de set. de 2026, 23:51 UTC

Correlated Moves

Quantumscape Corp shares are lower in after-market hours, breaking a recent trend of higher daily closes amid rising crude oil prices and inflationary pressures.

14 de set. de 2026, 23:51 UTC

Park Hotels & Resorts shares are lower in after-market hours, continuing a downward trend amid rising crude oil prices and broader market pressures.

14 de set. de 2026, 23:51 UTC

Baidu Inc. shares are higher in after-market trading, continuing a modest advance since Monday's close, despite remaining below the 20-day moving average.

14 de set. de 2026, 23:51 UTC

Shares of Synchrony Financial are higher in after-market trading, recovering from a recent low. Broader market factors include rising crude oil prices and inflation concerns.

14 de set. de 2026, 23:51 UTC

News

Shares of Gartner Inc are lower in after-market hours following unusual weakness, despite the recent launch of its IT Symposium/Xpo conference highlighting key technology trends.

14 de set. de 2026, 23:51 UTC

Correlated Moves

Social Media

SentinelOne Inc is trading lower in after-market hours amid broader market weakness and fluctuating oil prices ahead of the Federal Reserve's policy meeting.

14 de set. de 2026, 23:51 UTC

Correlated Moves

Ichor Holdings Ltd shares are higher in after-market trading, supported by a positive trend in the semiconductor sector and gains in Entegris Inc.

Comparação entre Pares

Variação de preço

Corvus Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

128.51% parte superior

Previsão para 12 meses

Média 29.5 USD 128.51%

Máximo 33 USD

Mínimo 27 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Corvus Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

4 ratings

Comprar

Manter

Vender

Com base em 4 analistas que deram avaliações de ações para Corvus Pharmaceuticals Inc - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.